Advancing digital health: FDA innovation during COVID-19

Digital health products have played an important role in the COVID-19 response, from supporting the remote monitoring of patients to enabling continuity in data collection for clinical trials. The U.S. Food and Drug Administration (FDA) has issued a number of temporary policies to support digital he...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kushal Kadakia, Bakul Patel, Anand Shah
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Acceso en línea:https://doaj.org/article/e6cd3676b6b641c1a1a0670ff13db78c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:e6cd3676b6b641c1a1a0670ff13db78c
record_format dspace
spelling oai:doaj.org-article:e6cd3676b6b641c1a1a0670ff13db78c2021-12-02T11:02:39ZAdvancing digital health: FDA innovation during COVID-1910.1038/s41746-020-00371-72398-6352https://doaj.org/article/e6cd3676b6b641c1a1a0670ff13db78c2020-12-01T00:00:00Zhttps://doi.org/10.1038/s41746-020-00371-7https://doaj.org/toc/2398-6352Digital health products have played an important role in the COVID-19 response, from supporting the remote monitoring of patients to enabling continuity in data collection for clinical trials. The U.S. Food and Drug Administration (FDA) has issued a number of temporary policies to support digital health innovation during the pandemic, such as guidance documents to expand the use of digital therapeutics for psychiatric disorders and medical devices for remote patient monitoring. In this article, we contextualize these policies to the agency’s existing regulatory framework for digital health, outline key considerations for patients and health care providers, and identify implications for the future of digital health innovation.Kushal KadakiaBakul PatelAnand ShahNature PortfolioarticleComputer applications to medicine. Medical informaticsR858-859.7ENnpj Digital Medicine, Vol 3, Iss 1, Pp 1-3 (2020)
institution DOAJ
collection DOAJ
language EN
topic Computer applications to medicine. Medical informatics
R858-859.7
spellingShingle Computer applications to medicine. Medical informatics
R858-859.7
Kushal Kadakia
Bakul Patel
Anand Shah
Advancing digital health: FDA innovation during COVID-19
description Digital health products have played an important role in the COVID-19 response, from supporting the remote monitoring of patients to enabling continuity in data collection for clinical trials. The U.S. Food and Drug Administration (FDA) has issued a number of temporary policies to support digital health innovation during the pandemic, such as guidance documents to expand the use of digital therapeutics for psychiatric disorders and medical devices for remote patient monitoring. In this article, we contextualize these policies to the agency’s existing regulatory framework for digital health, outline key considerations for patients and health care providers, and identify implications for the future of digital health innovation.
format article
author Kushal Kadakia
Bakul Patel
Anand Shah
author_facet Kushal Kadakia
Bakul Patel
Anand Shah
author_sort Kushal Kadakia
title Advancing digital health: FDA innovation during COVID-19
title_short Advancing digital health: FDA innovation during COVID-19
title_full Advancing digital health: FDA innovation during COVID-19
title_fullStr Advancing digital health: FDA innovation during COVID-19
title_full_unstemmed Advancing digital health: FDA innovation during COVID-19
title_sort advancing digital health: fda innovation during covid-19
publisher Nature Portfolio
publishDate 2020
url https://doaj.org/article/e6cd3676b6b641c1a1a0670ff13db78c
work_keys_str_mv AT kushalkadakia advancingdigitalhealthfdainnovationduringcovid19
AT bakulpatel advancingdigitalhealthfdainnovationduringcovid19
AT anandshah advancingdigitalhealthfdainnovationduringcovid19
_version_ 1718396325376032768